Navigation Links
MULTAQ(R) (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States

BRIDGEWATER, N.J., July 28 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that MULTAQ((R)) (dronedarone) 400 mg Tablets is now available in pharmacies in the United States. MULTAQ is an anti-arrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors (i.e., age >70, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter greater than or equal to 50 mm or left ventricular ejection fraction [LVEF] <40%), who are in sinus rhythm or who will be cardioverted.

MULTAQ was recently approved by the U.S. Food and Drug Administration on July 1, 2009.

"MULTAQ may help patients with atrial fibrillation or atrial flutter stay out of the hospital, which is an important factor in treatment that is often not addressed," said Gerald V. Naccarelli, M.D., Chief, Division of Cardiology, Pennsylvania State University College of Medicine. "We welcome a new option that may help patients with Afib or Aflutter manage their disease."

In the landmark ATHENA trial, the efficacy and safety of MULTAQ was evaluated in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% had NYHA class I-III stable heart failure). This trial showed that MULTAQ 400 mg BID, in addition to standard therapy, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24% (p<0.001) when compared to placebo, meeting the study's primary endpoint. This reduction was generally consistent across study subgroups based on baseline characteristics or medications. Patients taking MULTAQ had higher rates of diarrhea, nausea, bradycardia, QT-interval prolongation and cutaneous rash than patients taking placebo.

Initiation of MULTAQ treatment is contraindicated in patients with severe heart failure (NYHA class IV) or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than two-fold increase in mortality compared to placebo.

To ensure the use of MULTAQ in the appropriate patient population, sanofi-aventis U.S. LLC also announced the launch of mPACT MULTAQ((R)) Partnership for Appropriate Care and Treatment(TM), the Risk Evaluation and Mitigation Strategy (REMS). The mPACT Partnership was developed to assist healthcare professionals (HCPs) with the identification of appropriate patients and to ensure the safe use of MULTAQ while minimizing risk. The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance.

There are approximately 2.5 million Americans with AF and the incidence is growing worldwide in relation to the aging population. Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality.

About MULTAQ(R) (dronedarone)

MULTAQ, discovered and developed by sanofi-aventis, has been studied in a clinical development program involving nearly 6,300 patients including more than 3,200 patients who received MULTAQ. It represents one of the few new treatment options for AF/AFL patients in the last 10 years. MULTAQ is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. Treatment with MULTAQ can be initiated in an outpatient setting. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash.

Important Safety Information

MULTAQ is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II-III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. In a placebo-controlled study in patients with severe heart failure requiring recent hospitalization or referral to a specialized heart failure clinic for worsening symptoms (the ANDROMEDA study), patients given dronedarone had a greater than two-fold increase in mortality. Such patients should not be given dronedarone.

MULTAQ is also contraindicated in second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), bradycardia <50 bpm, QTc Bazett interval greater than or equal to 500 ms and severe hepatic impairment.

MULTAQ should not be given to patients who are or may become pregnant (Category X) or nursing.

MULTAQ should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval.

In patients with new or worsening heart failure, the suspension or discontinuation of MULTAQ should be considered.

Serum creatinine levels increase by about 0.1mg/dL following MULTAQ treatment initiation. The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation.

Hypokalemia and hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. Potassium levels should be maintained in the normal range pre and during administration.

For full prescribing information, please visit

About Atrial Fibrillation/Atrial Flutter

Atrial fibrillation is the most common arrhythmia, or irregular heartbeat, seen by physicians and accounts for about one-third of hospital admissions for cardiac rhythm disturbances. Hospitalization associated with AF has increased dramatically (two-to-three fold) in recent years in the U.S. Atrial flutter, another type of arrhythmia generating in the atrium, occurs less frequently, and may evolve into atrial fibrillation.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.


Multimedia News Release:

MULTAQ Web site:


    Marisol Peron
    Tel: 908-981-6565
    Mobile: 908-672-9051

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
2. CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter
3. Atrial fibrillation linked to increased hospitalization in heart failure patients
4. Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery
5. Atrial fibrillation in endurance athletes still poses problems for sports cardiologists
6. Frost & Sullivan: Momentum Mounting for Catheter Ablation Technologies in Treatment of Atrial Fibrillation
7. Health and Advocacy Leaders Mobilize to Bring Attention to Atrial Fibrillation, a Costly and Misunderstood Cardiovascular Disease
8. eCardio Launches NEW Atrial Fibrillation Information System (AFIS(TM))
9. Catheter Ablation Effective in Treating Atrial Fibrillation
10. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
11. Larger Men at Greater Risk for Atrial Fibrillation
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is ... and moderate facial wrinkling. While many patients are aware of the benefits of Botox® ... Botox® delivers to those suffering with discomfort, soreness, and pain as a result of ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... a double board certified facial plastic surgeon specializing in both surgical and non-surgical ... of The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained ...
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of ... Antonius Schuh, Ph.D., is scheduled to present a corporate ... Healthcare Conference. th Annual Piper Jaffray ... New York on Tuesday, December ... be available for one-on-one meetings during the conference. The ...
Breaking Medicine Technology: